Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWIFT Study of semaglutide for weight loss in adults living with HIV and obesity
2024-513168-24-00Phase 2Authorised
- Sponsor
- University College Dublin
- Start
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of semaglutide in obesity, Overweight and human immunodeficiency virus infection (HIV) (2 arms), sponsored by University College Dublin. Primary endpoint: Change in total body weight at week 28. Planned start Jun 2022; status: authorised.
02
Drugs
03
Conditions
obesityOverweighthuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-513168-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513168-24-00.